Developments in P2 receptor targeted therapeutics.
Williams
M
M
Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, IL 60064, USA. mike.williams@abbott.com
D000255:Adenosine Triphosphate / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D017209:Apoptosis; D015195:Drug Design; D004827:Epilepsy / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D010146:Pain / Q000188:drug therapy / Q000503:physiopathology; D018048:Receptors, Purinergic P2 / Q000187:drug effects / Q000502:physiology*; D009435:Synaptic Transmission; D014544:Uridine Triphosphate / Q000378:metabolism; D001743:Urinary Bladder / Q000187:drug effects / Q000502:physiology
D018048:Receptors, Purinergic P2; D000255:Adenosine Triphosphate; D014544:Uridine Triphosphate